trial

A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children

NCTId NCT01050582
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 244 (actual)
Sponsored by Johnson & Johnson
Primary completion 2011-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
244 (actual)
Study type
Interventional
Allocation
—
Model
Parallel
Masking
None
Start
2009-10
Primary completion
2011-07
Eligibility
ALL · 8 Years · 16 Years

Interventions & indications

Drugs
RisperidoneOther atypical antipsychotic drugs

Sponsors

Johnson & JohnsonLead Sponsor

Sites

0 total

Facts & assertions

4 sourced
Enrollment
244
Phase
PHASE4
Primary Completion Date
2011-07
Status
COMPLETED
relationships
The graph out of here
drug
Risperidone
drug
Other atypical antipsychotic drugs
drug
lead_sponsor
Johnson & Johnson
company
indication
Bipolar Disorder
indication
Conduct and Other Disruptive Behavior Disorders
indication
Behavior
indication